London and Oxford, United Kingdom – March 15, 2010: Matrix Corporate Capital ('Matrix') and PharmaVentures Limited ('PharmaVentures') today announced the signing of a Memorandum of Understanding ('MOU') covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe's dedicated healthcare investors.
PharmaTelevision Ltd announced today the launch of major new services to meet the growing demand for the production and dissemination of rich media content in the pharmaceutical and biotechnology sector. The company, a subsidiary of PharmaVentures, already provides the only online television channel dedicated to the bio-pharma industry, offering daily television news, analysis and feature interviews.
PharmaTelevision(R), the authoritative channel for the pharmaceutical, biotechnology and related industries, announced today the launch of its new service PharmaTelevision News (PTV News), the World's first daily television news and analysis programme for the sector.
PharmaTelevision, the authoritative channel for the pharmaceutical, biotechnology and related industries, announced today the launch of its new service, PharmaTelevision Premium Content. PTV Premium Content will include PTV News - a daily news and analysis service to be launched in August. Subscription to the service will be free until 30 September, 2009.
PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday.
PharmaTelevision announced today that it is to broadcast an exclusive interview with Dan Zabrowski, Global Head, Pharma Partnering, Roche Pharmaceuticals Division and Joe McCracken, Vice President, Business Development, Genentech, on the Roche:Genentech integration, on June 4th 2009.
Oxford, UK- 24 April 2009 - PharmaVentures Ltd, announced today that it has been engaged by Merck & Co, Inc. to advise and assist in divesting its world class research centre, the IRBM, located near Rome, Italy. The engagement will utilise PharmaVentures' pharmaceutical transactions experience in the healthcare and investment business sectors. The IRBM is an integrated, state-of-the-art small molecule and biological discovery centre. IRBM has an outstanding record of drug discovery including Isentress(R), the first approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award for the best pharmaceutical agent. The centre has received significant investment since 2000 and is staffed with exceptional, experienced pharmaceutical scientists.
Merck & Co and Schering-Plough have announced that they are to merge in a deal worth US$41.1 B. It's a deal that has been long speculated because of their existing marketing relationships over Zetia® and Vytorin® and the opportunity of potential cost savings. The combined company will generate sales of US$47 B.
If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies.'
In today's financial climate, the survival of smaller companies is often dependent on their ability to do deals successfully with larger pharmaceutical companies.